Zhitong Finance App News, Shiyao Group (01093.HK) announced that the first innovative drug developed by the Group - a novel potent and selective 5-serotonin (5-HT) /norepinephrine (NE) double reuptake inhibitor (SNRIs) amxetine hydrochloride enteric tablets (HA1406)) in the treatment of patients with depression (Test Plan No.: HA1406 — 007) has successfully reached the pre-set main efficacy endpoints. The test results have significant statistical differences and clear clinical benefits. HA1406 has shown excellent efficacy and safety, and is expected to be a first-line treatment for depression.

Zhitong Finance App News, Shiyao Group (01093.HK) announced that the first innovative drug developed by the Group - a novel potent and selective 5-serotonin (5-HT) /norepinephrine (NE) double reuptake inhibitor (SNRIs) amxetine hydrochloride enteric tablets (HA1406)) in the treatment of patients with depression (Test Plan No.: HA1406 — 007) has successfully reached the pre-set main efficacy endpoints. The test results have significant statistical differences and clear clinical benefits. HA1406 has shown excellent efficacy and safety, and is expected to be a first-line treatment for depression.